A Randomised Multicentre Trial Of Involved Field Radiotherapy Versus Involved Field Radiotherapy Plus Chemotherapy In Combination With Rituximab (Mabthera®) For Stage I – II Low Grade Follicular Lymphoma

For patients with stage I and II low grade follicular lymphoma radiotherapy will cure 40-50% of cases. This study is comparing standard therapy (radiotherapy) and investigational therapy (radiotherapy plus chemotherapy) to see if adding chemotherapy extends the time until the lymphoma progresses in those patient that will not be cured.

Primary Sponsor

Trans Tasman Radiation Oncology Group (TROG)

Collaborating Groups

ALLG (NHLLOW 5); Princess Margaret Hospital, Toronto

Final Accrual

150

Closing Date of Accrual

July 2012

Trial Chairperson

A/Prof Michael Mac Manus, Peter MacCallum Cancer Centre, VIC

Trial Contact

Bev.McClure@petermac.org

Clinical Trial Registration

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

Related Post

Dr Anna Lawless, EI SIG Chair 2025
10 December, 2025

Shaping the future: How TROG’s Emerging Investigators group is breaking down barriers for new researchers

SPECIAL INTEREST GROUP IN FOCUS: 10 December 2025 Dr

9 December, 2025

TROG’s inaugural Km’s for Cancer Research brings community together to support our work

LATEST NEWS: 9 December 2025 As we wrap up